MENU ABOUT US MAKE A DONATION
The Epoch Times
Login
SEARCH
CLOSE
Help Center subscribe newsletter Newsstands Epoch Shop Gift
  • TOP NEWS
  • SPECIAL SERIES
  • SPECIAL COVERAGE
  • LATEST ARTICLES
  • US
    • US News
    • US Features
    • US Politics
    • US Crime News
    • New York
    • San Francisco
    • Los Angeles
  • Opinion
    • Thinking About China
    • Viewpoints
    • Unbridled Evil: The Corrupt Reign of Jiang Zemin in China
    • The Reader’s Turn
  • China News
    • US-China Relations
    • Chinese Regime
    • Business & Economy
    • Chinese Culture
    • China Human Rights
    • Social Issues
    • Organ Harvesting in China
  • World News
    • Africa News
    • Americas
    • Asia & Pacific
    • Canada
    • Europe
    • UK News
    • Australia News
    • International
    • Middle East
  • Business & Markets
    • Companies
    • Economy
    • Markets
    • Real Estate
    • Gold and Commodities
  • ARTS & CULTURE
    • Fine Arts & Craftsmanship
    • Performing Arts
    • Books
    • Traditional Culture
    • Shen Yun Special Coverage
    • Film & TV
  • Science
    • News
    • Space
    • Environment
  • Tech
    • Tech News
    • Tech Products & Reviews
    • Social Media
  • Sports
  • Videos
    • American Thought Leaders
    • China Insider
    • Crossroads
  • Bright
    • Lifestyle
    • Inspired
    • Family & Education
    • Personal Finance
    • American Essence
  • Entertainment
    • Film & TV
    • Entertainment News
  • Health
    • Experts
    • Conditions
    • Life & Wellness
  • Special Topics
    • Battlefields
SEARCH
  • EpochTV
  • US
  • US Politics
  • Opinion
  • World News
  • China
  • Hong Kong
  • Health
  • Bright
  • Arts
  • Falun Gong
  • Premium
  • Markets
  • Games
  • Livestream
  • More

Gilead

  • US Regulators Clear Remdesivir for COVID-19 Outpatient Use
    US Regulators Clear Remdesivir for COVID-19 Outpatient Use
    Some nonhospitalized patients seeking treatment for COVID-19 can now use the antiviral remdesivir after U.S. drug regulators on Jan. 21 expanded approval of the drug. The Food and Drug Administration ...
    January 22, 2022BY Zachary Stieber
  • FDA Approves First Treatment for COVID-19, Remdesivir
    FDA Approves First Treatment for COVID-19, Remdesivir
    The U.S. Food and Drug Administration on Thursday approved Gilead Sciences's antiviral drug remdesivir for the treatment of adults ...
    October 22, 2020BY Mimi Nguyen Ly
  • EU Buys Remdesivir to Treat 30,000 COVID Patients, Seeks More
    EU Buys Remdesivir to Treat 30,000 COVID Patients, Seeks More
    BRUSSELS—The European Union's executive said on Wednesday it had agreed to buy a limited supply of the COVID-19 ...
    July 29, 2020BY Reuters
  • Gilead’s $2,340 Price for Coronavirus Drug Draws Criticism
    Gilead’s $2,340 Price for Coronavirus Drug Draws Criticism
    The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will ...
    June 30, 2020BY The Associated Press
  • NIH Trial: Gilead’s Drug Works Best in COVID Patients on Oxygen
    NIH Trial: Gilead’s Drug Works Best in COVID Patients on Oxygen
    The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences ...
    May 23, 2020BY Reuters
  • Remdesivir Explained—What Makes This Drug Work Against Viruses?
    Remdesivir Explained—What Makes This Drug Work Against Viruses?
    With the FDA approving Gilead’s Remdesivir as an emergency use treatment for the most acute cases of COVID-19, many people ...
    May 6, 2020BY The Conversation
  • 3,000 Participants Added to Trials for Experimental COVID-19 Treatment
    3,000 Participants Added to Trials for Experimental COVID-19 Treatment
    Gilead Sciences has increased the number of patients involved in two trials for its experimental COVID-19 treatment remdesivir. ...
    April 10, 2020BY Zachary Stieber
  • CCP Virus Patients Rush to Join Studies of Gilead Drug
    CCP Virus Patients Rush to Join Studies of Gilead Drug
    The new CCP virus made Dr. Jag Singh a patient at his own hospital. His alarm grew as ...
    April 6, 2020BY The Associated Press
  • How Much of Our Tax Money Goes to Big Pharma? A Lot.
    How Much of Our Tax Money Goes to Big Pharma? A Lot.
    After an 18 month investigation into the high cost of Gilead's hepatitis C drug Sovaldi—initially listed at $84,000 ...
    February 20, 2016BY Martha Rosenberg
  • Drug Maker Was Focused on Profits, Not Patients: Report
    Drug Maker Was Focused on Profits, Not Patients: Report
    WASHINGTON—The makers of a breakthrough hepatitis drug put profits before patients in pricing the $1,000 pill that's become ...
    December 1, 2015BY The Associated Press
TOP NEWS
  • FDA Investigates New Cyclospora Outbreak as Cases on Rise Across Midwest
    NEW By Kimberly Hayek
    FDA Investigates New Cyclospora Outbreak as Cases on Rise Across Midwest
  • Trump Denounces Communism, Touts Trump Accounts for Children in Georgia Speech
    2hr By Travis Gillmore
    Trump Denounces Communism, Touts Trump Accounts for Children in Georgia Speech
  • 124 Swiss Lawmakers Condemn Beijing’s Transnational Repression of Falun Gong
    2hr By Arthur Zhang
    124 Swiss Lawmakers Condemn Beijing’s Transnational Repression of Falun Gong
  • Live From Capitol Hill: ‘Unbroken’ Panel Discussion on Artistic Freedom
    2hr By Epoch Video
    Live From Capitol Hill: ‘Unbroken’ Panel Discussion on Artistic Freedom
  • The New Cholesterol Pill Isn’t for Everyone. Here’s How to Tell.
    3hr By Sheramy Tsai
    The New Cholesterol Pill Isn’t for Everyone. Here’s How to Tell.
  • Senate Panel Advances Bill to Make Hospitals Compete on Price
    3hr By Lawrence Wilson
    Senate Panel Advances Bill to Make Hospitals Compete on Price
  • House Adopts Budget Blueprint for $95 Billion Reconciliation Package
    4hr By Jackson Richman
    House Adopts Budget Blueprint for $95 Billion Reconciliation Package
  • House Passes Congressional Stock Trading Ban
    4hr By Jackson Richman and Nathan Worcester
    House Passes Congressional Stock Trading Ban
  • US Signs Nuclear Cooperation Deal With Saudi Arabia
    4hr By Emel Akan
    US Signs Nuclear Cooperation Deal With Saudi Arabia
  • Allergy Medication Recalled Over Possible ‘Life-Threatening’ Risks
    5hr By Jack Phillips
    Allergy Medication Recalled Over Possible ‘Life-Threatening’ Risks
The Epoch Times
Copyright © 2000 - 2026 The Epoch Times Association Inc. All Rights Reserved.
Back Top